Q3 2025 · 13F-HR
Column Group LLCholdings as filed
Filed 2025-11-14 · accession 0001193125-25-282923
$81.0M
Reported value
5
Positions
2025-09-30
Period end
The Brief · Column Group LLC · Q3 2025
AI · grounded in 13F
Column Group LLC trimmed its position in RAPT Therapeutics Inc by 87.5%. The fund added no new positions during the period. Total assets under management stood at $80,959,078 across five holdings.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 68622P109 | ORIC | ORIC Pharmaceuticals Inc. | $42.5M | 52.5% | 3,540,777 | Common | SOLE |
| 86889P109 | — | Surrozen, Inc. | $19.3M | 23.9% | 1,499,773 | Common | SOLE |
| 87990A106 | TNYA | Tenaya Therapeutics, Inc. | $14.9M | 18.3% | 9,400,290 | Common | SOLE |
| 75382E109 | — | RAPT Therapeutics Inc | $4.3M | 5.29% | 166,075 | Common | SOLE |
| 76155X100 | RVMD | Revolution Medicines Inc | $2,148 | 0.00% | 46 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.